Arkolith/Insider Trading/ADVM/Form 4

Fischer Laurent

CEO, PRESIDENT AND DIRECTOR, DirectorAdverum Biotechnologies, Inc. (ADVM) · full profile →Form 4 · filed Dec 10, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
16
5 non-derivative · 11 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 9, 2025Option exercise(M)150K$4.20$630K352K
Dec 9, 2025Tender(U)352K——0
Dec 9, 2025Tender(U)25K——0
Dec 9, 2025Grant(A)500K—$0523K
Dec 9, 2025Tender(U)523K——0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 9, 2025Disposed to issuer(D)110K——0
Dec 9, 2025Disposed to issuer(D)32K——0
Dec 9, 2025Disposed to issuer(D)58K——0
Dec 9, 2025Disposed to issuer(D)68K——0
Dec 9, 2025Disposed to issuer(D)63K——0
Dec 9, 2025Disposed to issuer(D)45K——0
Dec 9, 2025Disposed to issuer(D)68K——0
Dec 9, 2025Disposed to issuer(D)120K——0
Dec 9, 2025Option exercise(M)150K——0
Dec 9, 2025Disposed to issuer(D)200K——0
Dec 9, 2025Disposed to issuer(D)93K——0

Transaction Codes

M
Option exercise / conversion
U
See SEC Form 4 code table
A
Grant / award
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001379344-25-000006) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML